GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength

RBC Capital Markets expects GSK to deliver a broadly in-line third quarter, with weaker vaccine sales offset by strength in HIV treatments and respiratory drug Nucala. The broker reiterated its Sector Perform rating and 1,975p price target ahead of results on 28 October; GSK shares were at 1,771p when the note was published.

Analysis

The key issue is not whether the quarter clears a low bar, but whether growth in HIV and Nucala is durable enough to offset vaccine weakness without degrading the portfolio’s growth and earnings mix. A clean headline beat driven by those franchises could still fail to rerate the shares if management cannot distinguish temporary vaccine demand softness from a longer-lasting reset. Conversely, evidence that vaccine demand is stabilizing would reduce the risk that investors treat the offsets as merely defensive.

Near term, the 28 October report is a catalyst for segment-level guidance and demand commentary, not simply the reported total. Over 1–3 months, prescription and sales trends will matter more than one quarter’s mix; over 6–18 months, sustained HIV and respiratory growth must demonstrate that it can carry the portfolio while vaccines normalize. The broker’s in-line view limits the information value of an ordinary result; avoid assuming the stated target is a reliable catalyst. The thesis weakens if management lowers full-year expectations, HIV or Nucala growth decelerates, or vaccine weakness persists without a clear explanation. No independent evidence here establishes the durability or profitability of the offsets.

Key Decisions for Investors

• No high-conviction pre-earnings directional trade: an in-line setup offers limited edge, while segment-level guidance can move the thesis more than the headline result.
• After results, consider a measured long in GSK only if management maintains the outlook and provides evidence that HIV and Nucala growth can absorb vaccine softness; reassess if either franchise decelerates or guidance is cut.
• Track vaccine demand commentary and segment growth through the next 1–3 months. A persistent decline without a stabilization signal falsifies the offset thesis; improving trends across all three businesses would strengthen it.
• Treat competitive commentary in HIV and respiratory as a read-through risk, but verify product-level trends and guidance before expressing a peer or sector pair trade.